Pleural and Thoracic Air-Leak Complications After Hematopoietic Cell Transplantation: Diagnosis and Procedural Management.
- 1Department of Pulmonary and Critical Care Medicine, Mayo Clinic Health System, 1221 Whipple St., Eau Claire, WI 54703, USA.
- 2Division of Pulmonary, Critical Care, Hyperbaric, Allergy, and Sleep Medicine, Department of Medicine, Loma Linda University School of Medicine, Loma Linda, CA 92350, USA.
- 3Division of Pulmonary, Critical Care, and Sleep Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA.
Abstract
Pleural and thoracic air-leak complications after hematopoietic cell transplantation (HCT) are clinically important but underrepresented in broad post-transplant pulmonary reviews. Direct evidence is concentrated in adult allogeneic HCT. In a cohort of 618 adults, clinically significant pleural effusion had a 1-year cumulative incidence of 9.9% (95% confidence interval, 7.7-12.5%). A separate computed tomography-based cohort of 178 first allogeneic HCT recipients reported a day-100 cumulative incidence of 41.0%; these estimates are not directly comparable because the populations, ascertainment methods, endpoints, and follow-up differed. In 50 HCT recipients undergoing thoracentesis, a specific diagnosis was established in 26%, with 5 pneumothoraces and 0 hemothoraces. Thoracic air-leak syndrome is uncommon but carries poor outcomes in reported adult and pediatric series. This focused narrative review distinguishes direct HCT evidence from data extrapolated from hematologic malignancy, general pleural practice, critical care, interventional radiology, and cellular therapy. We organize evaluation by urgency, transplant phase, and radiographic pattern; define chronic graft-versus-host disease serositis as a diagnosis of exclusion; summarize chylothorax and pleural infection management; and provide procedure-specific safety considerations for thoracentesis, small-bore drainage, indwelling pleural catheters, intrapleural enzyme therapy, and pleural biopsy. No prospective HCT-specific trials validate these procedural pathways. Clinicians should therefore use ultrasound or image guidance; apply procedure-specific rather than uniform hemostatic thresholds; and integrate infection risk, platelet trajectory, anticoagulant exposure, oxygenation, operator setting, and expected benefit. The two clinical frameworks presented are proposed and non-validated.
Related
- Syndrome-oriented CNS infectious complications after hematopoietic stem-cell transplantation and CAR T-cell therapy, part 1—viral encephalitis, meningitis, and myelitis: recommendations from the Practice Harmonization & Guidelines Committee of the EBMT
- Kidney Injury in Adults After Hematopoietic Stem Cell Transplantation: Acute Kidney Injury, Transplant-Related Complications, and Long-Term Outcomes
- Hematopoietic Cell Transplantation in Children with Sickle Cell Disease: A Single-Center Experience and Exploration of an Age Threshold for Post-Transplant Complications
- Increased Susceptibility to Long-Term Complications in Leukemia Survivors Who Received Hematopoietic Stem Cell Transplantation During Adolescence
- A randomized controlled trial of a multidisciplinary collaborative fatigue management program for patients undergoing hematopoietic stem cell transplantation: study protocol
BibTeX
@article{shiari2026pleural,
title = {{Pleural and Thoracic Air-Leak Complications After Hematopoietic Cell Transplantation: Diagnosis and Procedural Management.}},
author = {Aryan Shiari and Lamia Aljundi and Ayman O Soubani},
journal = {Advances in respiratory medicine},
year = {2026},
month = oct,
doi = {10.3390/arm94050071},
url = {https://europepmc.org/article/MED/42930049},
note = {CC BY},
}
RIS
TY - JOUR
TI - Pleural and Thoracic Air-Leak Complications After Hematopoietic Cell Transplantation: Diagnosis and Procedural Management.
AU - Aryan Shiari
AU - Lamia Aljundi
AU - Ayman O Soubani
PY - 2026
DA - 2026/10/01
JO - Advances in respiratory medicine
DO - 10.3390/arm94050071
UR - https://europepmc.org/article/MED/42930049
AB - Pleural and thoracic air-leak complications after hematopoietic cell transplantation (HCT) are clinically important but underrepresented in broad post-transplant pulmonary reviews. Direct evidence is concentrated in adult allogeneic HCT. In a cohort of 618 adults, clinically significant pleural effusion had a 1-year cumulative incidence of 9.9% (95% confidence interval, 7.7-12.5%). A separate computed tomography-based cohort of 178 first allogeneic HCT recipients reported a day-100 cumulative incidence of 41.0%; these estimates are not directly comparable because the populations, ascertainment methods, endpoints, and follow-up differed. In 50 HCT recipients undergoing thoracentesis, a specific diagnosis was established in 26%, with 5 pneumothoraces and 0 hemothoraces. Thoracic air-leak syndrome is uncommon but carries poor outcomes in reported adult and pediatric series. This focused narrative review distinguishes direct HCT evidence from data extrapolated from hematologic malignancy, general pleural practice, critical care, interventional radiology, and cellular therapy. We organize evaluation by urgency, transplant phase, and radiographic pattern; define chronic graft-versus-host disease serositis as a diagnosis of exclusion; summarize chylothorax and pleural infection management; and provide procedure-specific safety considerations for thoracentesis, small-bore drainage, indwelling pleural catheters, intrapleural enzyme therapy, and pleural biopsy. No prospective HCT-specific trials validate these procedural pathways. Clinicians should therefore use ultrasound or image guidance; apply procedure-specific rather than uniform hemostatic thresholds; and integrate infection risk, platelet trajectory, anticoagulant exposure, oxygenation, operator setting, and expected benefit. The two clinical frameworks presented are proposed and non-validated.
SN - 2451-4934
SN - 2543-6031
ER -